Lumenis® Announces Research, Development and Licensing Agreement with Wellman Center for Photomedicine

Date Announced: 01 Nov 2011

Fostering new indications for Lumenis' UltraPulse CO₂ laser platform.

Lumenis Ltd. the world's largest medical laser company and a global developer, manufacturer and seller of laser and light-based devices for aesthetic, ophthalmic, and surgical applications, announced today that it has entered into a joint research, development and licensing agreement with Wellman Center for Photomedicine at Massachusetts General Hospital, the world's largest academic research facility dedicated to light-based biomedical research.

Despite recent developments in dermatology, there are many indications yet to be explored. The goal of the partnership is to develop new treatments that will progress the field by expanding indications and improving patient outcomes.

"This partnership aligns two great leaders in the field of laser dermatology," said Robert Mann, Senior VP and General Manager, Global Aesthetic and Dermatology for Lumenis. "Together we are in a stronger position to innovate more quickly, foster new indications based on our unique UltraPulse CO2 platform, the highest performing ablative platform in industry, and advance this field in new directions."

Dr. Dieter Manstein, physician and physicist with Wellman, was the lead creator and co-inventor of fractional laser technology and has advanced hair removal and many other dermatology innovations. Much of Dr. Manstein’s work utilizes Lumenis’ UltraPulse CO2 technology, widely accepted as a standard of care for fractional dermatologic procedures.

"We are very excited to engage in a significant translational research and development agreement with Lumenis," said Dr. Manstein. "This partnership creates a great opportunity to allow our teams to accelerate innovation, explore new and exciting indications, and ultimately improve patient care. The unique specifications of the UltraPulse system provides us with opportunities not available with typical systems."

"This partnership with Wellman Center for Photomedicine is particularly exciting for Lumenis because it is a continuation of a legacy," said Dov Ofer, President and CEO of Lumenis. "Wellman was pivotal in the validation of the UltraPulse CO2 laser for skin resurfacing during its inception in the 1990s.

Source: Lumenis

Contact

E-mail: via web site

Web Site: www.lumenis.com